News on lab-developed tests and emerging diagnostic technologies.
The company's test volume during the quarter shrank to just over 1,000 samples compared to 1,405 in the same period last year.
The company had no Q2 revenues and continues to advance DetermaVu, its liquid biopsy lung cancer diagnostic test, toward commercialization.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The revenue increase was driven by surging direct sales of the firm's diagnostic test cartridges in Europe, the Middle East, and Asia.
The company is continuing to work with a financial advisor to evaluate strategic options, with discussions about potential transactions ongoing.
